Maeda Tsuyoshi, Tatematsu Michiko, Muro Kei
Dept. of Pharmacy, Kasugai Municipal Hospital.
Gan To Kagaku Ryoho. 2011 Jun;38(6):963-6.
We retrospectively investigated the incidence of infusion reactions following cetuximab chemotherapy in 93 patients with colorectal cancer. Patients received chemotherapy treatment from September 2008 to February 2010 at Aichi Cancer Center Hospital. The initial cetuximab dose was 400 mg/m(2), followed weekly by an additional 250 mg/m(2), and biweekly by 500 mg/m(2). Infusion reactions were observed in 12 patients (13%), with grade 1 reactions in 6 patients and grade 2 reactions in 6 patients. Eleven of the 12 patients (92%) experienced infusion reactions during the first treatment. Typical grade 1 adverse events were fever and chills, nausea, vomiting and pruritus. Non-steroidal anti-inflammatory drugs were given for fever and chills. Grade 2 adverse events included dyspnea and wheezing, eruption, facial flushing and convulsions. Steroids were given for these symptoms. Infusion reactions were observed in 3 of the 12 patients (25%) <15 min after intravenous injection, 16-60 min after injection in 3 more patients (25%), and 61-120 min after injection in the remaining 6 patients (50%).
我们回顾性调查了93例结直肠癌患者接受西妥昔单抗化疗后输注反应的发生率。患者于2008年9月至2010年2月在爱知县癌症中心医院接受化疗治疗。西妥昔单抗初始剂量为400mg/m²，随后每周追加250mg/m²，每两周追加500mg/m²。12例患者（13%）出现输注反应，其中1级反应6例，2级反应6例。12例患者中有11例（92%）在首次治疗期间出现输注反应。典型的1级不良事件为发热、寒战、恶心、呕吐和瘙痒。针对发热和寒战给予非甾体类抗炎药。2级不良事件包括呼吸困难、喘息、皮疹、面部潮红和惊厥。针对这些症状给予类固醇药物。12例患者中有3例（25%）在静脉注射后<15分钟出现输注反应，另外3例患者（25%）在注射后16 - 60分钟出现反应，其余6例患者（50%）在注射后61 - 120分钟出现反应。
